Navigation Links
Insulin Ultrasensitive EIA Diabetes and Obesity Markers 008-10-1132-01

ProductsInsulin Ultrasensitive EIA Diabetes and Obesity Markers 008-10-1132-01
Company ALPCO Diagnostics
Item Insulin Ultrasensitive EIA Diabetes and Obesity Markers 008-10-1132-01
Features 
Description Insulin is the principal hormone responsible for the control of glucose metabolism. It is synthesized in the b-cells of the islets of Langerhans as the precursor, proinsulin, which is processed to form C-peptide and insulin. Both are secreted in equimolar amounts into the portal circulation. The mature insulin molecule is comprised of two polypeptide chains, the A-chain and B-chain (21 and 30 amino acids, respectively). The two chains are linked together by two inter-chain disulphide bridges. There is also an intra-chain disulphide bridge in the A-chain. The ALPCO Ultra-Sensitive Insulin ELISA is a solid phase enzyme immunoassay. It is based on the direct sandwich technique in which two monoclonal antibodies are directed against separate antigenic determinants on the human insulin molecule. During incubation, insulin in the sample reacts with peroxidase-conjugated anti-insulin antibodies and anti-insulin antibodies bound to the microplate wells. A simple washing step removes unbound enzyme labeled antibody. The bound conjugate is detected by reaction with 3,3',5,5'-tetramethylbenzidine (TMB). The reaction is stopped by adding acid. The colorimetric endpoint is read spectrophotometrically.
Info ALPCO DiagnosticsCall ALPCO Diagnostics to buy products (US and Canada only; other locations use number below) USACanada1-866-466-7731

Customer Service: (800) 592-5726
Web site: http://www.alpco.com

Related medicine products :

1. IGF-1 EIA Endocrine Function 026-AC-27F1 Insulin Growth Factor
2. Iso-Insulin EIA Diabetes and Obesity Markers 008-10-1128-01
3. Insulin EIA Diabetes and Obesity Markers 008-10-1113-01
4. Insulin Jumbo EIA Diabetes and Obesity Markers 008-10-1113-99
5. IGF-BP3 EIA Endocrine Function 022-IGF-E03 Insulin Growth Factor binding protein
6. Iso-Insulin ELISA
7. Insulin Autoantibody (IAA)
8. RIA kit for Insulin
9. Insulin ELISA Kit
10. Insulin RIA Test
11. AutoDELFIA® Insulin Kit
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: